150 related articles for article (PubMed ID: 36551506)
1. Role of Epidermal Growth Factor Receptor-Specific CAR-T Cells in the Suppression of Esophageal Squamous Cell Carcinoma.
Cheng C; Cui H; Liu H; Wu Y; Ding N; Weng Y; Zhang W; Cui Y
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551506
[TBL] [Abstract][Full Text] [Related]
2. Development of chimeric antigen receptor-modified T cells for the treatment of esophageal cancer.
Yu F; Wang X; Shi H; Jiang M; Xu J; Sun M; Xu Q; Addai FP; Shi H; Gu J; Zhou Y; Liu L
Tumori; 2021 Aug; 107(4):341-352. PubMed ID: 32988314
[TBL] [Abstract][Full Text] [Related]
3. EphA2 chimeric antigen receptor-modified T cells for the immunotherapy of esophageal squamous cell carcinoma.
Shi H; Yu F; Mao Y; Ju Q; Wu Y; Bai W; Wang P; Xu R; Jiang M; Shi J
J Thorac Dis; 2018 May; 10(5):2779-2788. PubMed ID: 29997940
[TBL] [Abstract][Full Text] [Related]
4. Targeting CD276 by CAR-T cells induces regression of esophagus squamous cell carcinoma in xenograft mouse models.
Xuan Y; Sheng Y; Zhang D; Zhang K; Zhang Z; Ping Y; Wang S; Shi X; Lian J; Liu K; Zhang Y; Li F
Transl Oncol; 2021 Aug; 14(8):101138. PubMed ID: 34052626
[TBL] [Abstract][Full Text] [Related]
5. CD276 suppresses CAR-T cell function by promoting tumor cell glycolysis in esophageal squamous cell carcinoma.
Yue G; Tang J; Zhang L; Niu H; Li H; Luo S
J Gastrointest Oncol; 2021 Feb; 12(1):38-51. PubMed ID: 33708423
[TBL] [Abstract][Full Text] [Related]
6. Correlation of epidermal growth factor receptor overexpression with increased epidermal growth factor receptor gene copy number in esophageal squamous cell carcinomas.
Yang YL; Xu KL; Zhou Y; Gao X; Chen LR
Chin Med J (Engl); 2012 Feb; 125(3):450-4. PubMed ID: 22490401
[TBL] [Abstract][Full Text] [Related]
7. EGFR-targeted CAR-T cells are potent and specific in suppressing triple-negative breast cancer both
Xia L; Zheng ZZ; Liu JY; Chen YJ; Ding JC; Xia NS; Luo WX; Liu W
Clin Transl Immunology; 2020 May; 9(5):e01135. PubMed ID: 32373345
[TBL] [Abstract][Full Text] [Related]
8. Distinct effects of EGFR inhibitors on epithelial- and mesenchymal-like esophageal squamous cell carcinoma cells.
Yoshioka M; Ohashi S; Ida T; Nakai Y; Kikuchi O; Amanuma Y; Matsubara J; Yamada A; Miyamoto S; Natsuizaka M; Nakagawa H; Chiba T; Seno H; Muto M
J Exp Clin Cancer Res; 2017 Aug; 36(1):101. PubMed ID: 28764725
[TBL] [Abstract][Full Text] [Related]
9. Expression of nucleostemin, epidermal growth factor and epidermal growth factor receptor in human esophageal squamous cell carcinoma tissues.
Zhang G; Zhang Q; Zhang Q; Yin L; Li S; Cheng K; Zhang Y; Xu H; Wu W
J Cancer Res Clin Oncol; 2010 Apr; 136(4):587-94. PubMed ID: 19823871
[TBL] [Abstract][Full Text] [Related]
10. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
Front Immunol; 2021; 12():665970. PubMed ID: 34475869
[TBL] [Abstract][Full Text] [Related]
11. Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines.
Fukuoka S; Kojima T; Koga Y; Yamauchi M; Komatsu M; Komatsuzaki R; Sasaki H; Yasunaga M; Matsumura Y; Doi T; Ohtsu A
Oncotarget; 2017 Feb; 8(7):11020-11029. PubMed ID: 28038457
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor protein overexpression and gene amplification are associated with aggressive biological behaviors of esophageal squamous cell carcinoma.
Lin G; Sun XJ; Han QB; Wang Z; Xu YP; Gu JL; Wu W; Zhang GU; Hu JL; Sun WY; Mao WM
Oncol Lett; 2015 Aug; 10(2):901-906. PubMed ID: 26622592
[TBL] [Abstract][Full Text] [Related]
13. Significance of elevated ERK expression and its positive correlation with EGFR in Kazakh patients with esophageal squamous cell carcinoma.
Cui X; Li S; Li T; Pang X; Zhang S; Jin J; Hu J; Liu C; Yang L; Peng H; Jiang J; Liang W; Suo J; Li F; Chen Y
Int J Clin Exp Pathol; 2014; 7(5):2382-91. PubMed ID: 24966948
[TBL] [Abstract][Full Text] [Related]
14. Development of GPC3 and EGFR-dual-targeting chimeric antigen receptor-T cells for adoptive T cell therapy.
Li K; Qian S; Huang M; Chen M; Peng L; Liu J; Xu W; Xu J
Am J Transl Res; 2021; 13(1):156-167. PubMed ID: 33527015
[TBL] [Abstract][Full Text] [Related]
15. EGFR inhibitors prevent induction of cancer stem-like cells in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition.
Sato F; Kubota Y; Natsuizaka M; Maehara O; Hatanaka Y; Marukawa K; Terashita K; Suda G; Ohnishi S; Shimizu Y; Komatsu Y; Ohashi S; Kagawa S; Kinugasa H; Whelan KA; Nakagawa H; Sakamoto N
Cancer Biol Ther; 2015; 16(6):933-40. PubMed ID: 25897987
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer.
Feng K; Guo Y; Dai H; Wang Y; Li X; Jia H; Han W
Sci China Life Sci; 2016 May; 59(5):468-79. PubMed ID: 26968708
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-133b/EGFR axis regulates esophageal squamous cell carcinoma metastases by suppressing anoikis resistance and anchorage-independent growth.
Zhu JF; Liu Y; Huang H; Shan L; Han ZG; Liu JY; Li YL; Dong X; Zeng W
Cancer Cell Int; 2018; 18():193. PubMed ID: 30479571
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma.
Hong MH; Heo SG; Lee YG; Kim HS; Park KU; Kim HG; Ko YH; Chung IJ; Min YJ; Kim MK; Kim KR; Yoo J; Kim TM; Kim HR; Cho BC
Cancer; 2020 Oct; 126(20):4521-4531. PubMed ID: 32749686
[TBL] [Abstract][Full Text] [Related]
19. Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas.
Gonzaga IM; Soares-Lima SC; de Santos PT; Blanco TC; de Reis BS; Quintella DC; de Oliveira IM; de Faria PA; Kruel CD; Andreollo NA; de Simão TA; Pinto LF
BMC Cancer; 2012 Dec; 12():569. PubMed ID: 23207070
[TBL] [Abstract][Full Text] [Related]
20. An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies.
Hu XY; Wang R; Jin J; Liu XJ; Cui AL; Sun LQ; Li YP; Li Y; Wang YC; Zhen YS; Miao QF; Li ZR
Mol Oncol; 2019 Feb; 13(2):246-263. PubMed ID: 30372581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
